Protein-protein interactions (PPIs) are essential mediators of both physiological and pathological biology that until recently have been considered very challenging to target therapeutically with small molecules. The recent approval of PPI inhibitory drugs such as venetoclax (a BCL-2-BAX antagonist) 1,2 and the continuing clinical progression of others, such as MDM2-p53 antagonists 3, 4 and BET bromodomain antagonists [5] [6] [7] , demonstrate that certain types of PPIs can be effectively targeted with small molecules 8 . A common feature of these druggable PPIs is the presence of a reasonably sized pocket, or groove, on the surface of the targeted protein that binds to a short peptide sequence in its interacting partner protein. Because these protein pockets have the appropriate size, shape and physicochemical features to bind to drug-like small molecules, such compounds can effectively compete for binding with the physiological peptide regions of the target protein, thereby disrupting the PPI.
, demonstrate that certain types of PPIs can be effectively targeted with small molecules 8 . A common feature of these druggable PPIs is the presence of a reasonably sized pocket, or groove, on the surface of the targeted protein that binds to a short peptide sequence in its interacting partner protein. Because these protein pockets have the appropriate size, shape and physicochemical features to bind to drug-like small molecules, such compounds can effectively compete for binding with the physiological peptide regions of the target protein, thereby disrupting the PPI.
Our greater appreciation of the structural and chemical features of targetable PPIs, together with increasing knowledge of functional protein interaction networks, strongly argue that there are likely to be many more therapeutic opportunities embedded in the human protein interactome. The likelihood of exploiting these opportunities is increased by recent improvements in highthroughput methods for the screening of small molecules that bind to proteins, such as thermal stabilization 9 , affinity selection-mass spectrometry 10 , DNA-encoded libraries 11 and high-throughput fragment screening 12 . Methods of directly screening for the disruption of a PPI have also advanced considerably over the past decade, including the use of fluorescence polarization 13 , time-resolved fluorescence energy transfer and Alpha (PerkinElmer) and NanoLuc (Promega) technologies.
One of the most abundant protein interaction domains in the human proteome is the WD40 repeat (WDR) domain, with more than 360 domains currently annotated. The WDR domain is typically a seven-bladed β-propeller domain with an overall doughnut shape. Importantly, the 'doughnut hole' or central pore of the WDR domain frequently mediates interactions with peptide regions of key interaction partners and sometimes has appropriate size and physico chemical features for high-affinity binding to drug-like small molecules. WDR domains are often essential subunits of multi protein complexes involved in a wide range of cellular processes, including G protein-coupled receptor (GPCR) signalling, DNA damage sensing and repair, the ubiquitinproteasome system (UPS), cell growth and division, epigenetic regulation of gene expression and chromatin organization, and the immune system. Here, we review recent progress and future opportunities for therapeutic targeting of human WDR domain-containing proteins.
High-throughput fragment screening
The screening of chemical libraries composed of chemical fragments (molecules smaller than 300 Da) typically at high concentration using direct binding rather than enzymatic assays.
Fluorescence polarization
Fluorescence-based binding assay that relies on the fact that free molecules rotate faster than large molecular complexes.
WDR domain structure
The blades of a WDR domain each contain a conserved serine-histidine and tryptophan-aspartate (WD) motif. Structural adaptability enables WDR domains to retain their β-propeller fold even upon deletion or insertion of WD repeats, the number of which can vary from five to eight, but is usually seven 14, 15 (FIG. 1a) . WDR domains typically act as scaffolds, often within large multi protein complexes 16 . The top, bottom and side surfaces of the WDR domain doughnut can simultaneously act as interaction sites for diverse binding partners, including proteins, peptides, RNA and DNA, such that multiple surfaces may potentially be targeted by chemical inhibitors. For instance, EZH2, SUZ12 and an activating histone peptide all exploit distinct surfaces of the WDR domaincontaining protein EED within the Polycomb repressive complex 2 (PRC2) (FIG. 1b) , and the WDR domain of DNA damage-binding protein 2 (DDB2) binds to damaged DNA (FIG. 1c) . WDR domains can also specifically recognize post-translational modifications on proteins: EED binds to trimethylated lysines 17 , WD repeat-containing protein 5 (WDR5) binds to methylated arginines 18 and yeast cell division control protein 4 (Cdc4) and human F-box/WD repeat-containing protein 7 (FBXW7) bind to phosphothreonine or phosphoserine degron motifs via their central cavity 19, 20 (FIG. 1d) .
Most likely as a result of their versatility as protein interaction scaffolds, WDR domains are the fourth most abundant domain in the human proteome 16 . In yeast, for which the interactome is best characterized, WDR domains are engaged in more PPIs than any other domain 16 , emphasizing the ubiquitous role of these domains in connecting the global protein interaction network. A systematic search identified 361 WDR domain-containing proteins in humans (Supplementary information S1 (table) ), but this number is probably a conservative estimate, as WDR domain sequences are weakly conserved outside of their signature WD di-peptide motifs and consequently are poorly annotated in public databases. An algorithm designed to detect WD repeats has recently identified up to 610 confirmed or predicted WDR domain-containing proteins in humans 21, 22 . Finally, the WDR domain is part of a larger class of β-propeller domains, the members of which bear no sequence similarity but have structurally similar folds. These domains, such as the Kelch domain, also form many potentially targetable PPI interfaces 23 .
Disease-associated WDR domains
As a consequence of their prevalence in the human proteome, WDR domains are involved in a wide spectrum of cellular networks, many of which are perturbed in human diseases. Cellular pathways from the Reactome database 24 were ranked based on the number of WDR proteins involved (FIG. 2; Supplementary information S2 (table) ). At the top of the list, at least 49 WDR domain-containing proteins are known to participate in the regulation of gene expression. Among these, 15 are components of chromatin complexes, including EED and WDR5, for which potent inhibitors have been reported [25] [26] [27] . WDR domains are also found in pathways that are targeted by existing drugs, such as DNA repair or the immune system; in emerging areas of drug discovery, such as chromatin-mediated signalling or splicing; and in cellular networks that have so far proved largely undruggable, such as the extensive UPS that exerts post-translational control over most of the proteome.
In some cases, disease association is direct and causative. For instance, recognition of a cyclin E phosphothreonine degron motif by the central pocket of the WDR domain of FBXW7 leads to cyclin E degradation, which restrains DNA replication and thereby helps ensure genome stability. Loss-of-function mutations in the gene that encodes FBXW7, including a mutation hot spot at R465, the side chain that recognizes phosphothreonine, lead to accumulation of cyclin E and are recurrent driver events in endometrial, colorectal and other cancers 28 (FIG. 1d) . In another example, mapping missense variations from clinical and population genetics onto the 3D structure of the WDR domain-containing protein TBL1XR1 clearly separates pathogenic mutations that are responsible for severe neurological disorders in children from benign polymorphisms 29 .
In addition to being associated with disease gene networks, many WDR domain-containing proteins are target candidates for therapy in cancer, metabolic disorders, neurological diseases and regenerative medicine (TABLE 1) . Although these putative targets remain to be fully validated, the WDR domain is potentially a common yet unexploited entry point for drug discovery in many disease areas.
Epigenetic targets in oncology
Epigenetic mechanisms are central to the aetiology of many cancers 30, 31 , and proteins involved in chromatinmediated signalling are a promising target class for cancer therapy 32, 33 . At least 15 WDR domain-containing proteins are components of chromatin complexes (FIG. 2) , and some may be valid drug targets. For example, inhibition of WDR5 with PPI antagonists has recently emerged as a promising strategy in oncology. WDR5 is a binding partner of the histone-lysine N-methyltransferases MLL1-4 (also known as histone-lysine N-methyltransferase 2A, 2D, 2C and 2D, respectively), SETD1A and SETD1B. WDR5 recruits MLL1 to specific genomic loci that are known to be misregulated in more than 5% of acute myeloid leukaemias through an interaction between WDR5 and p30, an oncogenic variant of the transcription factor CCAAT/enhancer binding protein α (C/EBPα). MLL1 in turn methylates lysine 4 of histone 3 (H3K4), an epigenetic signal associated with active gene transcription. The net result -inhibition of myeloid differentiation -is dependent on the presence of p30 at these loci 25 . The drug-like chemical probe OICR-9429 occupies the MLL1 binding pocket of WDR5 (FIG. 3a) , disrupts the MLL1-WDR5 interaction, reduces MLL1 activity at p30-occupied loci and selectively kills patient-derived acute myeloid leukaemia cells that express p30 (REF. 25 ).
Another study with this WDR5 inhibitor exploited the observation that prevalent cancer-promoting gain-of-function mutations in TP53 upregulate the transcription of MLL1 and MLL2, which leads to a global increase in histone methylation and cancer cell proliferation. Disrupting the MLL1-containing complex with OICR-9429 selectively lowered the proliferation of such TP53 gain-of-function mutant cancer cells 34 . A related study was based on the observation that leukaemogenesis induced by the MLL-AF9 fusion protein requires co-expression of the wild-type MLL1-encoding allele 35 . MM-401, a macrocyclic inhibitor of WDR5 that binds to the same pocket as OICR-9429, antagonized the interaction of WDR5 with wild-type MLL1, inhibited the methyl transferase activity of wild-type MLL1 and induced myeloid differentiation of mixed lineage leukaemia cells, with no apparent toxicity towards normal bone marrow cells 36 . More recently, the WDR domain-containing protein EED was uncovered as a promising therapeutic target. EED is a component of PRC2 and is necessary for the activity of the PRC2 catalytic subunit EZH2, a histone methyltransferase that epigenetically silences gene expression and is the target of inhibitors currently in phase I and phase II clinical trials against diffuse large B cell lymphomas [38] [39] [40] [41] . Two recent studies 26, 27 have independently shown that drug-like inhibitors that target the WDR domain of EED (A-395 and EED226) can antagonize binding of an activating peptide that is necessary for the efficient propagation of the methyl mark deposited by PRC2 along chromatin (FIG. 3b) . The compounds inhibited PRC2 in cells with low nanomolar IC 50 values and were active against cell lines with mutations in PRC2 that render the complex resistant to catalytic inhibitors currently in clinical trials in oncology 26, 27 . EED interacts directly with EZH2, and an EZH2-derived stapled helix targeting EED disrupted PRC2 in cells 42, 43 . It is encouraging that a clinical trial for the EED antagonist MAK683 (a chemical analogue of EED226) has recently been initiated in patients with diffuse large B cell lymphoma (clinicaltrials.gov identifier: NCT02900651).
The WDR domain-containing protein RBBP4 is another component of PRC2 and other chromatin complexes, including the nucleosome remodelling and histone deacetylase (NuRD) complex and the chromatin assembly factor 1 (CAF1) complex 44 . The structural role of RBBP4 in various complexes and its function in transcriptional reprogramming of cancer cells is not clear but probably varies with cancer types and grades. Recent data revealed that RBBP4 regulates chromatin assembly during repair of DNA damage, and genetic disruption of RBBP4 sensitizes glioblastoma cells to DNA lesions following treatment with the standard-of-care chemotherapeutic drug temozolomide 45 . WDR77 (also known as MEP50), another WDR domain-containing protein involved in epigenetic control of gene expression, directly binds to protein arginine N-methyltransferase 5 (PRMT5) to promote symmetrical dimethylation of arginine side chains on histone and non-histone substrates. PRMT5 is upregulated in lymphomas and some solid tumours. Preclinical PRMT5 inhibitors show dose-dependent antitumour activity in an animal model of mantle-cell lymphoma 46 , and a dose escalation study of PRMT5 inhibitors in patients with solid tumours and non-Hodgkin lymphoma was recently initiated (NCT02783300). Deletion of the gene encoding S-methyl-5ʹ-thioadenosine phosphorylase (MTAP), which occurs in 40% of glioblastomas and in other cancer types, leads to enhanced dependency on PRMT5 in cells, although this has not yet been confirmed with PRMT5 inhibitors 47, 48 . The PRMT5-WDR77 complex was also shown to remodel gene expression to promote epithelial-to-mesenchymal transition and cancer cell invasion 49 . Resistance mechanisms may arise for catalytic PRMT5 inhibitors, and targeting the PRMT5-WDR77 interaction to inhibit PRMT5 function may be a useful strategy for the development of second-generation compounds against tumours that are dependent on PRMT5 activity.
Other oncology targets Many WDR domain-containing proteins are implicated in cancer-associated cellular pathways other than epigenetic mechanisms. Thirteen or more WDR domain-containing proteins play a role in the UPS. One of these, cell division cycle protein 20 homologue (CDC20) is a co-activator of the anaphase-promoting complex (APC/C; also known as the cyclosome), an E3 ubiquitin ligase that recruits substrates for ubiquitylation in order to allow the completion of mitosis 50 . CDC20 is upregulated in numerous cancer Nature Reviews | Drug Discovery Figure 2 | WD40 repeat domain-containing proteins perform diverse cellular functions. The number of WD40 repeat (WDR) domain-containing proteins associated with Reactome pathways and corresponding enrichment compared with the whole proteome are indicated. Specific disease-associated examples are shown in coloured boxes. Note that β-TrCP is a commonly used alias for BTRC. AAAS, aladin; APAF1, apoptotic protease-activating factor 1; ARPC1A, actin-related protein 2/3 complex subunit 1A; CDC20, cell division cycle protein 20 homologue; CHAF1B, chromatin assembly factor 1 subunit B; CSTF1, cleavage stimulation factor subunit 1; DAW1, dynein assembly factor with WDR repeat domains 1; DCAF4, DDB1-and CUL4-associated factor 4; DDB2, DNA damage-binding protein 2; DTL, denticleless protein homologue; DMXL1, DmX-like protein 1; DYNC1I1; cytoplasmic dynein 1 intermediate chain 1; ELP2, elongator complex protein 2; FBXW7, F-box/WD repeat-containing protein 7; FZR1, Fizzy-related protein homologue; LRRK2, leucine-rich repeat serine/threonine-protein kinase 2; MLST8, target of rapamycin complex subunit LST8; PAAF1, proteasomal ATPase-associated factor 1; PAFAH1B1, platelet-activating factor acetylhydrolase 1B subunit α; PALB2, partner and localizer of BRCA2; PIK3R4, phosphoinositide 3-kinase regulatory subunit 4; PLAA, phospholipase A-2-activating protein; PLRG1, pleiotropic regulator 1; PPP2R2B, serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B β isoform; PRPF19, pre-mRNA-processing factor 19; RAE1, mRNA export factor; RBBP4, retinoblastoma-binding protein 4; RPTOR, regulatory-associated protein of mTOR; SNRNP40, U5 small nuclear ribonucleoprotein 40 kDa protein; STRN4, striatin-4; TAF5, transcription initiation factor TFIID subunit 5; Ub, ubiquitin; UPS, ubiquitin-proteasome system; VPRBP, DDB1-and CUL4-associated factor 1; WDR5, WD repeat-containing protein 5; WDHD1, WD repeat and HMG-box DNA-binding protein 1; WSB1, WD repeat and SOCS box-containing protein 1. types and is repressed by ectopic introduction of p53; silencing of CDC20 induces G2-M arrest and suppresses cancer cell growth 51 . CDC20 is systematically upregulated in glioblastoma relative to low-grade gliomas and drives the invasiveness and self-renewal of glioblastoma stem-like cells; CDC20 knockdown induces cell cycle arrest and apoptosis in glioblastoma tumour-initiating cells [52] [53] [54] . These results suggest that small molecules that disrupt the interaction between CDC20 and APC/C, or antagonize CDC20-mediated recruitment of APC/C substrates, could have therapeutic value against glioblastoma and potentially other cancer types.
Genetic aberrations recurrently found in cancer often drive tumour initiation or tumour growth. For instance, chromosomal translocations fuse the WDR domain of transport protein SEC31A, a protein involved ALK, anaplastic lymphoma kinase; APC/C, anaphase-promoting complex; BRCA2, breast cancer type 2 susceptibility protein; CAF-1, chromatin assembly factor 1; CAMKK2, calcium/calmodulin-dependent protein kinase kinase 2; CDC20, cell division cycle protein 20 homologue; C/EBPα, CCAAT/enhancer binding protein α; CHAF1B, chromatin assembly factor 1 subunit B; DCAF1, DDB1-and CUL4-associated factor 1; GNB3, guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit β3; HAT, histone acetyltransferase; HDAC, histone deacetylase; JAK2, Janus kinase 2; LRRK2, leucine-rich repeat serine/threonine-protein kinase 2; MTAP, S-methyl-5ʹ-thioadenosine phosphorylase; NuRD, nucleosome remodelling and histone deacetylase; PAFAH1B1, platelet-activating factor acetylhydrolase 1B subunit α; PALB2, partner and localizer of BRCA2; PARP, poly(ADP-ribose) polymerase; PKC, protein kinase C; PRC2, Polycomb repressive complex 2; PRMT5, protein arginine N-methyltransferase 5; RACK1, receptor of activated protein C kinase 1; RBBP4, retinoblastoma-binding protein 4; siRNA, small interfering RNA; WDR, WD repeat; WDR5, WD repeat-containing protein 5.
in the formation of transport vesicles from the endoplasmic reticulum, with the kinase domain of Janus kinase 2 (JAK2) in Hodgkin lymphoma 55 and with the kinase domain of anaplastic lymphoma kinase (ALK) in large B cell lymphomas 56, 57 . In both cases, chemical inhibitors targeting the kinase domain of the oncogenic fusion protein have an anti-proliferative effect 55, 57 , and pharmacological targeting of the WDR domain may be an alternative strategy to treat tumours with SEC31A translocations.
Partner and localizer of BRCA2 (PALB2) is another WDR domain-containing protein that is recurrently mutated in cancer. Homozygous mutations of PALB2 cause Fanconi anaemia and predispose individuals to childhood cancer 58, 59 , whereas heterozygous mutations resulting in truncation of the WDR domain are found in 1% of familial breast cancers 60 . PALB2 interacts with breast cancer type 2 susceptibility protein (BRCA2) and is required for BRCA2-mediated homologous recombination, double-strand break repair and tumour suppression 61 . Nature Reviews | Drug Discovery 26, 27 . A synthetic stapled helical peptide that binds at the opposite surface of EED also inhibits EZH2 binding and PRC2 function 42, 43 . BAM, β-addition motif; BRD, bromodomain; MCSS, motif connecting SANT1L and SANT2L; PHD, plant homeodomain; SANT, SWI3, ADA2, N-COR and TFIIIB; SET, Su(var)3-9, Enhancer-of-zeste and Trithorax.
Cancer-associated PALB2 mutants lose their ability to bind BRCA2 (REF. 62 ). Tumours that bear BRCA1, BRCA2 or PALB2 mutations are highly dependent on repair functions provided by the enzyme poly(ADP-ribose) polymerase (PARP), inhibitors of which are now in clinical use 63 . A PALB2 mutation that results in loss of the WDR domain predicts exceptional in vivo response to PARP inhibition 62, 63 . These data suggest that compounds targeting the WDR domain of PALB2 could be of value in tumours with genetic lesions in other components of the DNA-repair machinery.
Regenerative medicine WDR domain-containing proteins are promising candidate targets in the emerging field of regenerative medicine. Chromatin assembly factor 1 subunit B (CHAF1B; also known as CAF1 subunit B) mediates chromatin assembly during DNA replication 64 , and an RNA interference (RNAi) screen identified CHAF1A and CHAF1B as the top targets whose loss induces the reprogramming of mouse fibroblasts into pluripotent stem cells 65 . Suppression of CHAF1B also enhanced the conversion of B cells into macrophages and fibroblasts into neurons 65 . CHAF1B knockdown increased chromatin accessibility at enhancer domains associated with activation of pluripotency genes, confirming an epigenetic function of CHAF1B in maintaining somatic cell identity. CHAF1B is a subunit of the CAF1 complex, and it is likely that the WDR domain of CHAF1B plays a structural role in stabilizing CAF1. This suggests that compounds targeting the WDR domain of CHAF1B inhibit CAF1 function and could therefore predispose cells to acquire a pluripotent chromatin landscape.
Interestingly, WDR5 has also recently been associated with pluripotency. Disruption of the MLL1-WDR5 interaction with the WDR5 antagonist MM-401 leads to global redistribution of monomethylated H3K4 at enhancer elements, represses lineage determinant genes and reprogrammes mouse epiblast stem cells to have a naive pluripotency, such that over 50% of treated epiblasts exhibit naive embryonic stem cell features after 3 days of treatment 66 .
Neurological disorders
The WDR domain-containing protein platelet-activating factor acetylhydrolase 1B subunit α (PAFAH1B1, also known as LIS1) is required for actin polymerization in cerebellar and hippocampal neurons and functions with dynein to mediate coupling of the nucleus to the centrosome during neuronal migration 67 . Deletion of or point mutations in PAFAH1B1 cause neuronal migration defects and can lead to neurological disorders and brain malformation 68, 69 . Conversely, overexpression of PAFAH1B1 resulting from genomic amplification is associated with cerebellar atrophy in humans, and transgenic mice overexpressing PAFAH1B1 have impaired neural migration and smaller brains 70 . Mapping of point mutations associated with neural migration defects indicates that the WDR domain of PAFAH1B1 plays a central role in neural migration 70 . An inhibitor that targets the WDR domain of PAFAH1B1 may reduce the pathogenic effect of PAFAH1B1 amplification.
Mutation of Gly2019 to Ser in leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) is responsible for 1% of sporadic and 4% of hereditary Parkinson disease 71 . LRRK2 contains multiple domains, including a kinase, a GTPase and a WDR domain. Mutations driving Parkinson disease augment the kinase activity of LRRK2, and the neuronal toxicity of mutant LRRK2 can be reduced by alterations that decrease its kinase activity 72, 73 , placing the catalytic activity of LRRK2 at the root of the pathology. Chemical inhibitors targeting the kinase or GTP binding domains of LRRK2 protect against models of Parkinson disease, further supporting mutated LRRK2 as a target for therapy [74] [75] [76] . An LRRK2 construct that lacks the WDR domain is unable to auto-phosphorylate, and loss of the WDR domain blocks the neurotoxicity of multiple LRRK2 mutations 77, 78 . Pharmacological targeting of the WDR domain could therefore be an alternative strategy to ameliorate LRRK2 defects that cause Parkinson disease.
Other disease areas
The WDR protein guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit β3 (GNB3) is a Gβ subunit of a G protein complex that transduces GPCR signals to intracellular effector proteins and is highly expressed in the brain. The C825T synonymous polymorphism results in a splice variant with increased G protein activation and is associated with hypertension, diabetes and obesity 79, 80 . Duplication of a genomic region encompassing GNB3 is recurrently observed in children with a syndrome associated with obesity, intellectual disability and seizures, and transgenic mice carrying an extra copy of GNB3 have an increased body mass index 81 . These results connect GNB3 gene dosage to obesity. Like all other Gβ subunits, GNB3 is composed entirely of a seven-bladed WDR domain, and chemical probes that inhibit GNB3 interactions would be useful to investigate the merit of targeting this WDR protein in syndromes associated with GNB3 duplication. More generally, similar arguments would apply to the other Gβ subunits that mediate signalling responses to the ~800 known GPCRs in humans.
Receptor of activated protein C kinase 1 (RACK1; also known as GNB2L1) is a ubiquitous WDR domaincontaining protein that acts as a binding scaffold with a diverse array of interactors, including protein kinases, membrane receptors and 40S ribosomal subunits and is associated with multiple cell type-specific functions 82, 83 . Receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL) is a cytokine that elicits differentiation of bone marrow cells into osteoclasts and activation of bone resorption, leading to bone loss, via dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6; also known as MAPKK6), which activates numerous signalling pathways including the NF-κB, p38, JNK and extracellular signal-regulated kinase (ERK) pathways 84 . RACK1 acts as a scaffolding protein that recruits MAP2K6 to the MAPK signalling cascade triggered by RANKL, and silencing RACK1 reduces RANKLinduced bone loss in mice 85 . Small molecules disrupting the scaffolding function of RACK1, a protein exclusively composed of a WDR domain, may phenocopy the osteoclast-inhibiting effect of small interfering RNAs (siRNAs). RACK1 also facilitates translation by viruses containing internal ribosome entry sites and is an essential host factor for hepatitis C virus (HCV) infection, such that it may be a broad antiviral target 86 . Considering the ubiquitous nature and multiple functions of RACK1, the effects of its inhibition may depend on cell type and context, although silencing of RACK1 does not seem to overly affect cell viability and proliferation 86 . DDB1-and CUL4-associated factor 1 (DCAF1, also known as VPRBP) is another WDR domain-containing protein that is a putative antiviral host target. DCAF1 is composed of an atypical kinase domain that phosphorylates nucleosomal histone 2A 87 and a WDR domain that recruits substrate proteins to the CUL4A-RBX1-DDB1-DCAF1 E3 ubiquitin ligase complex for ubiquitylation and subsequent proteasomal degradation 88 . In HIV-1, the viral protein Vpr binds DCAF1 to hijack the CUL4A-RBX1-DDB1-DCAF1 complex to target antiviral proteins such as uracil-DNA glycosylase (UNG), thereby aberrantly committing protective host proteins to proteasome-mediated degradation 89 . Similarly, the HIV-2 protein Vpx binds DCAF1 to usurp the CUL4A-RBX1-DDB1-DCAF1 complex to degrade the antiviral protein SAM domain and HD domain-containing deoxynucleoside triphosphate triphosphohydrolase (SAMHD1) 90 . In another example, a conserved V protein from paramyxoviruses (a family of viruses that includes mumps virus, human parainfluenza virus type 2 and simian virus 5) can bind one of the WDR domains of DDB1 and recruit signal transducer and activator of transcription (STAT) proteins, which are critical transducers of the antiviral response, to the CUL4A-RBX1-DDB1-DCAF1 complex for proteasomal degradation 91 .
Compounds that target the WDR domain of DCAF1 or DDB1 may thus antagonize the illicit degradation of host defence factors by different viruses.
Pharmacologically targeting WDR domains
Considering that WDR domains are ubiquitous and often disease-associated, it comes as a surprise that only four WDR domain-containing proteins have been targeted pharmacologically so far: human WDR5, EED and CDC20 and yeast Cdc4 92, 93) . These published reports can be further grouped into two categories, depending on the specific location of the inhibitor-binding sites.
The WDR5 and EED inhibitors occupy the central pocket and bind with nanomolar potency [25] [26] [27] , whereas the CDC20 and Cdc4 inhibitors occupy side cavities and bind in the micromolar range 92, 93 (FIG. 4a) . OICR-9429, a potent and selective chemical probe targeting WDR5, was derived from a hit identified by screening a diverse library of 16,000 compounds using a fluorescence polarization assay to measure the displacement of the MLL1 peptide, followed by multiple rounds of structure-guided optimization 25, [94] [95] [96] . OICR-9429 binds WDR5 with an affinity of 50 nM as measured by isothermal titration calorimetry, inhibits the co-immunoprecipitation of an MLL peptide with WDR5 with an IC 50 of 223 nM and elicits a clear phenotypic response in cellular assays at 5 μM (REF. 25 ). A-395, a potent and novel PPI inhibitor that binds EED and inhibits the formation of PRC2, is derived from a hit initially identified via a highthroughput, small-molecule screen utilizing a thermal shift assay of EED protein as a readout 97 . The molecule was subsequently optimized by incorporating a strategic sp 3 -rich ring constraint and appending polar functionalities to increase potency while decreasing cLogP 26, 97 . EED226, another EED-targeting chemical probe, was developed from a hit in a high-throughput campaign to find compounds that inhibit the catalytic activity of the reconstituted PRC2 (REF. 27 ). Elucidating the mechanism of action of the screening hit enabled structure-guided fragmentation of the compound, regrowth and optimization into a potent, selective EED inhibitor 98, 99 . A-395 and EED226 display target-based cellular activity and substantial in vivo efficacy in mouse tumour models and are valuable chemical tools to further interrogate the role of PRC2 in tumour initiation and maintenance 26, 27 . Small-molecule ligands that bind WDR domains on the side of the doughnut naturally tend to insert between the WD40 blades and may occlude substrate interactions, as in the case of the CDC20 inhibitor apcin, which competitively blocks interaction of CDC20 with the destruction box motif in APC/C substrates 93 . The conformational flexibility of WDR domains enables protein interactions to be controlled allosterically, as illustrated in the case of Cdc4, the yeast orthologue of human FBXW7. A small molecule called SCF-I2 binds to a cryptic allosteric pocket on the side of the WD40 domain of Cdc4 and thereby triggers an elaborate series of main-chain rearrangements that result in partial occlusion of the main binding pocket that recognizes Cdc4 phosphodegron (CPD) motifs in substrates 92 . Interestingly, NMR evidence indicates that the allosteric pocket also weakly interacts with CPD motifs, suggesting a mechanism whereby multiple CPD substrates may engender the dynamic exchange of sites in 
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Apo state
The unbound state of a protein or other macromolecule, as opposed to the 'holo' state, when complexed to a ligand.
the main binding pocket in a single WD40 (REF. 100) . Whether other WDR domain-containing proteins are susceptible to allosteric inhibition remains to be seen.
Lessons from other β-propeller domains
Potent inhibitors of other β-propeller domains that are structurally related but do not belong to the WDR family also tend to target the central pocket (FIG. 4a) . In one recent example, fragment screening by X-ray crystallo graphy led to a chemical series that outcompetes the interaction of the Kelch domain-containing protein Kelch-like ECH-associated protein 1 (KEAP1), an adaptor subunit of the ubiquitin ligase CUL3, with its substrate nuclear factor erythroid 2-related factor 2 (NRF2), a critical transcription factor for oxidative stress-responsive genes 101 . The KEAP1 inhibitors bind the central cavity of the Kelch domain with nanomolar potency owing in part to a critical carboxylic acid that occupies a basic patch otherwise engaged by an aspartate residue of NRF2 (REF. 101 ). This type of charge-mediated binding mechanism may pose some difficulties for further drug development, given the potential issues with membrane permeability. The central cavities of numerous WDR domain-containing proteins engage charged side chains on interaction partners; for example, WDR5 and EED contact positively charged arginine and methyl-lysine residues, respectively, whereas Cdc4 and FBXW7 contact phosphothreonine residues. Nevertheless, the de novo development of potent inhibitors of β-propeller domains by fragment-based approaches may be generalizable to many other WDR domain-containing proteins.
A nanomolar inhibitor of viral neuraminidase also binds a central pocket in a β-propeller domain that contains the catalytic site and an adjacent cavity 102 , whereas pitstop2, a compound that exploits a side pocket of the terminal domain of clathrin heavy chain 1 (CLTC) to block its association with endocytic ligands, binds with micromolar potency 103 . The cyclic peptide antibiotic quinupristin, which is often used in combination with another streptogramin (dalfopristin), targets the 50S ribosomal subunit but also binds with micro molar affinity to the central cavity of the virginiamycin B lyase β-propeller domain, leading to linearization of the cyclic antibiotic and drug resistance 104 . Cyclic peptides can also bind the central cavity of WDR5 (REF. 36) and may be well adapted to target β-propeller domains in general. The anti-platelet drug tirofiban utilizes a third mechanism of action in which juxtaposed cavities from the β-propeller domain of integrin α2b and an unrelated domain of integrin β3 both contribute to the binding pocket 105 . Finally, in an intriguingly divergent structural mechanism, a number of natural ligands have been identified that actually stabilize PPIs.
In the first such example, the small molecule plant hormone auxin acts as an agonist of the β-propeller protein transport inhibitor response 1 (TIR1) by occupying a small cleft in the central cavity at the interface between TIR1 and its substrate peptide IAA7, thereby stabilizing the TIR1-IAA7 interaction to enable IAA7 ubiquitylation by the SCF TIR1 complex 106 (FIG. 4b) .
Similarly, jasmonate, another plant hormone, acts as a molecular glue at the interface of the β-propeller F-box protein coronatine-insensitive protein 1 (COI1) and a JAZ1 (also known as TIFY 10A) substrate peptide 107 .
Structural chemistry of WDR domain inhibition
Comparison of the structure of the most potent WDR domain antagonists reveals extensive chemical diversity, illustrated by A-395 and EED226, two compounds that occupy the same pocket of EED (FIG. 4c) . A feature shared by WDR5, EED and KEAP1 inhibitors is the positioning of a ring decorated with three R groups at the centre of the binding pocket. One of the R groups extends deep inside the central channel, whereas the other two project against the walls at the entrance of the binding site. It will be interesting to see whether future WDR domain inhibitors also satisfy this seemingly propitious arrangement that efficiently exploits the central cavity of β-propeller domains. Importantly for drug discovery, the chemical diversity of WDR domain inhibitors also reflects the substantial structural diversity of WDR domain pockets, owing to the low sequence identity of WDR domains. Notably, these pockets are intrinsically malleable as a result of the conformational flexibility of the β-propeller domain. This structural diversity even extends to pockets that share similar ligands. For instance, arginine side chains of PHD finger protein 6 (PHF6) and MLL1 serve as anchoring residues in the central pockets of RBBP4 and WDR5, respectively, but important differences in side chains at key positions surrounding the bound arginines are found between RBBP4 and WDR5 (FIG. 4d) . This suggests that achieving selectivity within this target class may not be as much of a challenge as for other protein classes that share binding pockets with similar chemical features, such as kinases or bromodomains. Indeed, the highly potent antagonists of EED do not bind to WDR5, nor does the potent WDR5 inhibitor OICR-9429 bind to EED 25, 26 . Furthermore, a chemoproteomics experiment using a derivatized version of OICR-9429 identified only WDR5 as an enriched binding protein from cellular lysates 25 . Conformational rearrangement of a limited number of side chains can have a dramatic effect on the size and geometry of the WDR domain central pocket. For instance, four residues (F133, Y191, C261 and F263) control the volume of the top pocket of WDR5. In particular, the cavity is obstructed by F263 in the apo state, is partially open in the inhibitor-bound state and is forced by the arginine of the MLL peptide into a fully open state in which the bottom of the cavity opens up and the pocket is replaced with a tunnel that connects both sides of the WDR domain 25, 108 (FIG. 5a-c) . Similarly, the geometry of the EED inhibitor-binding site is regulated by the conformation of W364, Y365 and R367. Although the pocket is shallow in the apo and histonebound states, conformational rearrangement of Y365 and adjacent residues (engaged either directly or indirectly in aromatic cage formation) produces a larger, deeper cavity that can accommodate small-molecule inhibitors 26 ,27,97,99 (FIG. 5d-f ).
Taken collectively, these pioneering efforts to target WDR domains and other β-propeller domains suggest that the central cavity of the propeller may be the most tractable site for drug discovery, though the possibility of targeting other WDR domain surfaces cannot be ruled out.
The merits of targeting PPIs WDR domain-containing proteins typically perform scaffolding rather than catalytic functions. To inhibit a methyltransferase, a deubiquitinase or a histone acetyltransferase, the natural inclination is to target the catalytic domain, particularly if a well-defined druggable pocket is evident. However, targeting the catalytic site is not always readily achievable, and for many enzyme classes this is still very challenging. For instance, despite its potential as an oncology target, no catalytic inhibitor of MLL1 has been reported to date. Nevertheless, the methyltransferase function of MLL1 can be antagonized in cells by the WDR5 inhibitor OICR-9429 (REF. 25 ). Similarly, some of the intense but so far unsuccessful drug discovery efforts that have focused on ubiquitin ligases and deubiquitinases for the past decade might be more effective if redirected towards the numerous WDR domains that mediate PPIs in the UPS (FIG. 3) .
Targeting WDRs that bind to druggable enzymes can also have merit. The epigenetic regulator PRC2 is an instructive example to consider. Long-term treatment of cancer cells with inhibitors of EZH2, the catalytic component of PRC2, elicits a resistance mechanism triggered by mutations at the inhibitor-binding site 109, 110 . However, allosteric inhibitors targeting the WDR subunit, EED 26, 27 , retain on-target inhibition in cells resistant to catalytic inhibitors. Moreover, unlike catalytic inhibitors, prolonged treatment with an EED inhibitor failed to select for resistance mutations 26 . In another example, synthetic lethal pairs between cancer-associated mutations in components of the SWI/SNF chromatin remodelling complex and inhibition of EZH2 rely in some cases on a structural rather than an enzymatic function of EZH2, and EED inhibitors that disrupt PRC2, such as an EZH2 stapled helix, are active when catalytic EZH2 inhibitors are not 42 . Thus, targeting the WDR domain interaction hub of PRC2 offers several complementary approaches compared with targeting the catalytic domain. (FIG. 5) , structural studies of apo or peptide-bound structures may not always accurately predict the druggability of the central pocket. For situations in which WDR domains behave as docking platforms for electrostatically charged peptides, it will be challenging to find inhibitors sufficiently polar to compete with substrates, and sufficiently hydrophobic to cross cell membranes. It is also unclear whether the weak-binding compounds targeting side pockets of WDR domains reflect fundamentally poor druggability of these sites or simply the paucity of drug discovery efforts focused on these sites to date. Considering the size of the WDR domain-containing family and recent progresses in targeting PPIs, we expect that additional WDR domain-containing proteins will prove druggable in the future. An unknown variable in targeting WDR domains is the potential effect of perturbing multiple protein complexes. For instance, RBBP7 is part of the type B histone acetyltransferase complex required for chromatin assembly following DNA replication but is also a component of the NuRD complex and the PRC2 methyltransferase complex, all three of which are associated with transcriptional repression. In another example, the WDR protein RBBP5 is a component, with varying degrees of essentiality, of the complexes containing MLL1, MLL2, MLL3, MLL4, SETD1A and SETD1B 37 . The combined disruption of multiple independent molecular machineries may result in either increased overall efficacy or unexpected phenotypic outcomes, depending on the context. This reality argues strongly for the use of chemical probes to validate WDR domain targets using appropriate disease models in order to explore potential therapeutic windows [111] [112] [113] .
The presence of WDR domain-containing proteins in diverse E3 ubiquitin ligase complexes, and the seminal discovery of natural small-molecule ligands that bridge E3-substrate interactions in plants, raises the possibility that bidentate ligands that simultaneously bind the WDR domain of the E3 and a therapeutic target protein of interest may enable the proteasome-mediated elimination of the target protein. Indeed, thalidomide and its derivatives have been discovered to act in exactly this fashion, by bridging an ectopic interaction between the CUL4 substrate receptor subunit cereblon and the transcription factors Ikaros and Aiolos, which leads to the degradation of Ikaros and Aiolos and explains the efficacy of thalidomide against B cell malignancies 114, 115 . This molecular glue concept has been elaborated in the form of protein-targeting chimeric molecules, or Protacs 116, 117 , which, in some cases, have yielded a phenotypic outcome that is superior to mono-functional ligands that inhibit a specific domain of the target protein 118 . This principle may be more general than anticipated; it was recently found that anticancer sulfonamides ectopically target the oncoprotein RNA-binding protein 39 (RBM39) to the WDRcontaining protein DCAF15 for ubiquitylation by the CUL4 complex 119, 120 . It is not clear yet whether these sulfonamide drugs bind the WDR domain or another region of DCAF15, but E3-associated WDR domains may hold general therapeutic potential for chemically reharnessing the UPS with bivalent small-molecule ligands.
In conclusion, the ubiquitous, functionally versatile and often disease-associated WDR domain has a structurally diverse pocketome and is probably more druggable than meets the eye owing to its intrinsic conformational flexibility. Consequently, targeting WDR domains offers potential avenues to alter the catalytic, scaffolding and substrate-recognition functions of diverse enzyme complexes. Recent encouraging results for WDR domain inhibitors in epigenetic regulation hold great potential but still need to be validated in the clinic. The chemical tractability of WDR domains as a target class should be further explored, especially in areas of disease biology that have so far been undruggable by conventional approaches.
